An update for community-acquired bacterial pneumonia pharmacotherapy: What's new and where does it fit?

Journal of Pharmacy Practice

Volumn 25, Issue 6, 2012, Pages 569-575

  Debellis, Heather F ^a   Jones, Melissa C ^a   Kincaid, Scott E ^a  

^a SOUTHERN UNIVERSITY   (United States)

Author keywords

ceftaroline fosamil; pneumonia; tigecycline

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTRIAXONE; LEVOFLOXACIN; TIGECYCLINE;

ARTICLE; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; HEADACHE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INSOMNIA; LUNG CANCER; LUNG EMBOLISM; MORTALITY; MULTIDRUG RESISTANCE; NAUSEA; PATIENT SELECTION; PLEURA EFFUSION; PLEURA EMPYEMA; PNEUMONIA; RELAPSE; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN ALLERGY; TERATOGENICITY; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84870901623     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012460829     Document Type: Article

References (19)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 ; 44 (suppl 2). S27 - S72
2. Lim L, Sutton E, Brown J. Ceftaroline: a new broad-spectrum cephalosporin. Am J Health Syst Pharm. 2011 ; 68 (6). 491-498
3. Forest Laboratories2011. Safety and adverse event profile: Teflaro. http://www.teflaro.com/SP-AdverseEventProfile.aspx. Accessed September 19, 2011.
4. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs. 2009 ; 69 (14). 1879-1901
5. McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs. 2008 ; 68 (18). 2633-2644
6. Bhattacharya M, Parakh A, Narang M. Tigecycline. J Postgrad Med. 2009 ; 55 (1). 65-68
7. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 ; 26 (8). 1099-1110 (Pubitemid 44167819)
8. File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 ; 66 (suppl 3). iii19 - iii32
9. Low DE, File TM, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 ; 66 (suppl 3). iii33 - iii44
10. Rank DR, Friedland HD, Laudano JB.. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011 ; 66 (suppl 3). iii53 - iii59
11. St. Louis, MO: Forest Pharmaceuticals Inc ; 2010:
12. File TM, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010 ; 51 (12). 1395-1405
13. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumomia: results from a double-blind randomized phase 3 compairson study with levofloxacin. Diagn Microbiol Infect Dis. 2009 ; 63 (1). 52-61
14. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009 ; 9: 44
15. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011 ; 55 (3). 1162-1172
16. Philadelphia, PA: Wyeth Pharmaceuticals Inc ; 2011:
17. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008 ; 61 (3). 329-338 (Pubitemid 351858575)
18. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171 (4). 388-416
19. Gardiner D, Dukart G, Cooper A, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010 ; 50 (2). 229-238